Abstract | BACKGROUND AND AIMS: METHODS: This randomised, open label, parallel-group, single centre study enrolled post-menopausal women (50-70 years), with RA and osteopenia (T-score >-2.5) who were receiving stable dose of methylprednisolone 5 mg or equivalent within the previous 3 months, and expected to continue therapy for at least 12 months. Patients were treated with intramuscular neridronate 25 mg administered once a month, or oral alendronate 70 mg or oral risedronate 35 mg both administered once-weekly, for 12 months. The main outcome measure was adherence to treatment over 1 year, assessed using the Morisky Medication Adherence Scale 4-item (MMAS-4; adherence defined as patients with MMAS-4 score ≥3). RESULTS: Of 87 women (mean age 61.5 ± 9.2 years) enrolled, 30 were randomized to neridronate, 27 to alendronate and 30 to risedronate therapy. Adherence rates after 12 months were significantly higher with neridronate than with alendronate or risedronate (76.7% vs 47.8% and 48.0%; p<0.05 for both versus neridronate). After 12 months, lumbar and femoral neck BMD and DAS28 were significantly improved in all groups compared with baseline (p<0.05) with no significant difference between the three treatment groups. CONCLUSION:
|
Authors | Maurizio Muratore, Eugenio Quarta, Laura Quarta |
Journal | Acta bio-medica : Atenei Parmensis
(Acta Biomed)
Vol. 84
Issue 1
Pg. 23-9
(Jun 01 2013)
ISSN: 0392-4203 [Print] Italy |
PMID | 24189759
(Publication Type: Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Adrenal Cortex Hormones
- Diphosphonates
- Alendronate
|
Topics |
- Adrenal Cortex Hormones
- Alendronate
- Arthritis, Rheumatoid
- Bone Density
(drug effects)
- Diphosphonates
- Humans
- Treatment Outcome
|